Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Common Equity (2017 - 2025)

Historic Common Equity for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $436.0 million.

  • Arcus Biosciences' Common Equity fell 2283.19% to $436.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $436.0 million, marking a year-over-year decrease of 2283.19%. This contributed to the annual value of $485.0 million for FY2024, which is 497.84% up from last year.
  • Arcus Biosciences' Common Equity amounted to $436.0 million in Q3 2025, which was down 2283.19% from $549.0 million recorded in Q2 2025.
  • Over the past 5 years, Arcus Biosciences' Common Equity peaked at $842.0 million during Q4 2021, and registered a low of $436.0 million during Q3 2025.
  • In the last 5 years, Arcus Biosciences' Common Equity had a median value of $600.0 million in 2023 and averaged $611.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 37269.59% in 2021, then plummeted by 2968.04% in 2023.
  • Arcus Biosciences' Common Equity (Quarter) stood at $842.0 million in 2021, then decreased by 21.97% to $657.0 million in 2022, then decreased by 29.68% to $462.0 million in 2023, then rose by 4.98% to $485.0 million in 2024, then fell by 10.1% to $436.0 million in 2025.
  • Its Common Equity stands at $436.0 million for Q3 2025, versus $549.0 million for Q2 2025 and $531.0 million for Q1 2025.